Report Detail

Pharma & Healthcare Global Non-invasive Vaccine Market Growth 2022-2028

  • RnM4495542
  • |
  • 24 November, 2022
  • |
  • Global
  • |
  • 114 Pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

Noninvasive vaccine delivery systems need to incorporate an effective adjuvant, specially designed for triggering both mucosal and systemic immune responses.

The global market for Non-invasive Vaccine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Non-invasive Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Non-invasive Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Non-invasive Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Non-invasive Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Non-invasive Vaccine players cover Merck, GSK, Sanofi, Lanzhou Institute and Serum Institute, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Non-invasive Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Non-invasive Vaccine market, with both quantitative and qualitative data, to help readers understand how the Non-invasive Vaccine market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in Units.

Market Segmentation:
The study segments the Non-invasive Vaccine market and forecasts the market size by Type (Oral Vaccine and Nasal Spray Vaccine,), by Application (Public and Private.), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Oral Vaccine
Nasal Spray Vaccine

Segmentation by application
Public
Private

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
AstraZeneca
Cipla
BCHT

Chapter Introduction
Chapter 1: Scope of Non-invasive Vaccine, Research Methodology, etc.
Chapter 2: Executive Summary, global Non-invasive Vaccine market size (sales and revenue) and CAGR, Non-invasive Vaccine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Non-invasive Vaccine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Non-invasive Vaccine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Non-invasive Vaccine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol and PaxVax, etc.
Chapter 14: Research Findings and Conclusion


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Non-invasive Vaccine Annual Sales 2017-2028
    • 2.1.2 World Current & Future Analysis for Non-invasive Vaccine by Geographic Region, 2017, 2022 & 2028
    • 2.1.3 World Current & Future Analysis for Non-invasive Vaccine by Country/Region, 2017, 2022 & 2028
  • 2.2 Non-invasive Vaccine Segment by Type
    • 2.2.1 Oral Vaccine
    • 2.2.2 Nasal Spray Vaccine
  • 2.3 Non-invasive Vaccine Sales by Type
    • 2.3.1 Global Non-invasive Vaccine Sales Market Share by Type (2017-2022)
    • 2.3.2 Global Non-invasive Vaccine Revenue and Market Share by Type (2017-2022)
    • 2.3.3 Global Non-invasive Vaccine Sale Price by Type (2017-2022)
  • 2.4 Non-invasive Vaccine Segment by Application
    • 2.4.1 Public
    • 2.4.2 Private
  • 2.5 Non-invasive Vaccine Sales by Application
    • 2.5.1 Global Non-invasive Vaccine Sale Market Share by Application (2017-2022)
    • 2.5.2 Global Non-invasive Vaccine Revenue and Market Share by Application (2017-2022)
    • 2.5.3 Global Non-invasive Vaccine Sale Price by Application (2017-2022)

3 Global Non-invasive Vaccine by Company

  • 3.1 Global Non-invasive Vaccine Breakdown Data by Company
    • 3.1.1 Global Non-invasive Vaccine Annual Sales by Company (2020-2022)
    • 3.1.2 Global Non-invasive Vaccine Sales Market Share by Company (2020-2022)
  • 3.2 Global Non-invasive Vaccine Annual Revenue by Company (2020-2022)
    • 3.2.1 Global Non-invasive Vaccine Revenue by Company (2020-2022)
    • 3.2.2 Global Non-invasive Vaccine Revenue Market Share by Company (2020-2022)
  • 3.3 Global Non-invasive Vaccine Sale Price by Company
  • 3.4 Key Manufacturers Non-invasive Vaccine Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers Non-invasive Vaccine Product Location Distribution
    • 3.4.2 Players Non-invasive Vaccine Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Non-invasive Vaccine by Geographic Region

  • 4.1 World Historic Non-invasive Vaccine Market Size by Geographic Region (2017-2022)
    • 4.1.1 Global Non-invasive Vaccine Annual Sales by Geographic Region (2017-2022)
    • 4.1.2 Global Non-invasive Vaccine Annual Revenue by Geographic Region
  • 4.2 World Historic Non-invasive Vaccine Market Size by Country/Region (2017-2022)
    • 4.2.1 Global Non-invasive Vaccine Annual Sales by Country/Region (2017-2022)
    • 4.2.2 Global Non-invasive Vaccine Annual Revenue by Country/Region
  • 4.3 Americas Non-invasive Vaccine Sales Growth
  • 4.4 APAC Non-invasive Vaccine Sales Growth
  • 4.5 Europe Non-invasive Vaccine Sales Growth
  • 4.6 Middle East & Africa Non-invasive Vaccine Sales Growth

5 Americas

  • 5.1 Americas Non-invasive Vaccine Sales by Country
    • 5.1.1 Americas Non-invasive Vaccine Sales by Country (2017-2022)
    • 5.1.2 Americas Non-invasive Vaccine Revenue by Country (2017-2022)
  • 5.2 Americas Non-invasive Vaccine Sales by Type
  • 5.3 Americas Non-invasive Vaccine Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Non-invasive Vaccine Sales by Region
    • 6.1.1 APAC Non-invasive Vaccine Sales by Region (2017-2022)
    • 6.1.2 APAC Non-invasive Vaccine Revenue by Region (2017-2022)
  • 6.2 APAC Non-invasive Vaccine Sales by Type
  • 6.3 APAC Non-invasive Vaccine Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan

7 Europe

  • 7.1 Europe Non-invasive Vaccine by Country
    • 7.1.1 Europe Non-invasive Vaccine Sales by Country (2017-2022)
    • 7.1.2 Europe Non-invasive Vaccine Revenue by Country (2017-2022)
  • 7.2 Europe Non-invasive Vaccine Sales by Type
  • 7.3 Europe Non-invasive Vaccine Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Non-invasive Vaccine by Country
    • 8.1.1 Middle East & Africa Non-invasive Vaccine Sales by Country (2017-2022)
    • 8.1.2 Middle East & Africa Non-invasive Vaccine Revenue by Country (2017-2022)
  • 8.2 Middle East & Africa Non-invasive Vaccine Sales by Type
  • 8.3 Middle East & Africa Non-invasive Vaccine Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Non-invasive Vaccine
  • 10.3 Manufacturing Process Analysis of Non-invasive Vaccine
  • 10.4 Industry Chain Structure of Non-invasive Vaccine

11 Marketing, Distributors and Customer

  • 11.1 Sales Channel
    • 11.1.1 Direct Channels
    • 11.1.2 Indirect Channels
  • 11.2 Non-invasive Vaccine Distributors
  • 11.3 Non-invasive Vaccine Customer

12 World Forecast Review for Non-invasive Vaccine by Geographic Region

  • 12.1 Global Non-invasive Vaccine Market Size Forecast by Region
    • 12.1.1 Global Non-invasive Vaccine Forecast by Region (2023-2028)
    • 12.1.2 Global Non-invasive Vaccine Annual Revenue Forecast by Region (2023-2028)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Non-invasive Vaccine Forecast by Type
  • 12.7 Global Non-invasive Vaccine Forecast by Application

13 Key Players Analysis

  • 13.1 Merck
    • 13.1.1 Merck Company Information
    • 13.1.2 Merck Non-invasive Vaccine Product Offered
    • 13.1.3 Merck Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.1.4 Merck Main Business Overview
    • 13.1.5 Merck Latest Developments
  • 13.2 GSK
    • 13.2.1 GSK Company Information
    • 13.2.2 GSK Non-invasive Vaccine Product Offered
    • 13.2.3 GSK Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.2.4 GSK Main Business Overview
    • 13.2.5 GSK Latest Developments
  • 13.3 Sanofi
    • 13.3.1 Sanofi Company Information
    • 13.3.2 Sanofi Non-invasive Vaccine Product Offered
    • 13.3.3 Sanofi Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.3.4 Sanofi Main Business Overview
    • 13.3.5 Sanofi Latest Developments
  • 13.4 Lanzhou Institute
    • 13.4.1 Lanzhou Institute Company Information
    • 13.4.2 Lanzhou Institute Non-invasive Vaccine Product Offered
    • 13.4.3 Lanzhou Institute Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.4.4 Lanzhou Institute Main Business Overview
    • 13.4.5 Lanzhou Institute Latest Developments
  • 13.5 Serum Institute
    • 13.5.1 Serum Institute Company Information
    • 13.5.2 Serum Institute Non-invasive Vaccine Product Offered
    • 13.5.3 Serum Institute Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.5.4 Serum Institute Main Business Overview
    • 13.5.5 Serum Institute Latest Developments
  • 13.6 Valneva
    • 13.6.1 Valneva Company Information
    • 13.6.2 Valneva Non-invasive Vaccine Product Offered
    • 13.6.3 Valneva Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.6.4 Valneva Main Business Overview
    • 13.6.5 Valneva Latest Developments
  • 13.7 Shanghai United Cell
    • 13.7.1 Shanghai United Cell Company Information
    • 13.7.2 Shanghai United Cell Non-invasive Vaccine Product Offered
    • 13.7.3 Shanghai United Cell Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.7.4 Shanghai United Cell Main Business Overview
    • 13.7.5 Shanghai United Cell Latest Developments
  • 13.8 Bibcol
    • 13.8.1 Bibcol Company Information
    • 13.8.2 Bibcol Non-invasive Vaccine Product Offered
    • 13.8.3 Bibcol Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.8.4 Bibcol Main Business Overview
    • 13.8.5 Bibcol Latest Developments
  • 13.9 PaxVax
    • 13.9.1 PaxVax Company Information
    • 13.9.2 PaxVax Non-invasive Vaccine Product Offered
    • 13.9.3 PaxVax Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.9.4 PaxVax Main Business Overview
    • 13.9.5 PaxVax Latest Developments
  • 13.10 Vabiotech
    • 13.10.1 Vabiotech Company Information
    • 13.10.2 Vabiotech Non-invasive Vaccine Product Offered
    • 13.10.3 Vabiotech Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.10.4 Vabiotech Main Business Overview
    • 13.10.5 Vabiotech Latest Developments
  • 13.11 Tiantan Biological
    • 13.11.1 Tiantan Biological Company Information
    • 13.11.2 Tiantan Biological Non-invasive Vaccine Product Offered
    • 13.11.3 Tiantan Biological Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.11.4 Tiantan Biological Main Business Overview
    • 13.11.5 Tiantan Biological Latest Developments
  • 13.12 EuBiologics
    • 13.12.1 EuBiologics Company Information
    • 13.12.2 EuBiologics Non-invasive Vaccine Product Offered
    • 13.12.3 EuBiologics Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.12.4 EuBiologics Main Business Overview
    • 13.12.5 EuBiologics Latest Developments
  • 13.13 Panacea Biotec Ltd
    • 13.13.1 Panacea Biotec Ltd Company Information
    • 13.13.2 Panacea Biotec Ltd Non-invasive Vaccine Product Offered
    • 13.13.3 Panacea Biotec Ltd Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.13.4 Panacea Biotec Ltd Main Business Overview
    • 13.13.5 Panacea Biotec Ltd Latest Developments
  • 13.14 Bio-Med
    • 13.14.1 Bio-Med Company Information
    • 13.14.2 Bio-Med Non-invasive Vaccine Product Offered
    • 13.14.3 Bio-Med Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.14.4 Bio-Med Main Business Overview
    • 13.14.5 Bio-Med Latest Developments
  • 13.15 Halfkin Bio-Pharmaceuticals
    • 13.15.1 Halfkin Bio-Pharmaceuticals Company Information
    • 13.15.2 Halfkin Bio-Pharmaceuticals Non-invasive Vaccine Product Offered
    • 13.15.3 Halfkin Bio-Pharmaceuticals Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.15.4 Halfkin Bio-Pharmaceuticals Main Business Overview
    • 13.15.5 Halfkin Bio-Pharmaceuticals Latest Developments
  • 13.16 AstraZeneca
    • 13.16.1 AstraZeneca Company Information
    • 13.16.2 AstraZeneca Non-invasive Vaccine Product Offered
    • 13.16.3 AstraZeneca Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.16.4 AstraZeneca Main Business Overview
    • 13.16.5 AstraZeneca Latest Developments
  • 13.17 Cipla
    • 13.17.1 Cipla Company Information
    • 13.17.2 Cipla Non-invasive Vaccine Product Offered
    • 13.17.3 Cipla Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.17.4 Cipla Main Business Overview
    • 13.17.5 Cipla Latest Developments
  • 13.18 BCHT
    • 13.18.1 BCHT Company Information
    • 13.18.2 BCHT Non-invasive Vaccine Product Offered
    • 13.18.3 BCHT Non-invasive Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.18.4 BCHT Main Business Overview
    • 13.18.5 BCHT Latest Developments

14 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on Non-invasive Vaccine. Industry analysis & Market Report on Non-invasive Vaccine is a syndicated market report, published as Global Non-invasive Vaccine Market Growth 2022-2028. It is complete Research Study and Industry Analysis of Non-invasive Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
3,045.12
6,090.24
3,524.58
7,049.16
506,031.60
1,012,063.20
297,484.80
594,969.60
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report